Skip to main content

Advertisement

Table 1 Baseline characteristics of thalassemic and non-thlalassemic subjects

From: Dysregulation of the RANKL/RANK/OPG axis in thalassemia intermedia patients

Variable Non-thalassemic Thalassemic P-valuea
Gender (n)
 Females 16 15 0.515
 Males 23 29
 Total 39 44
Age (mean ± SD)b 24.59 ± 8.165 23.41 ±7.916 0.506
Hb, g/dl (mean ± SD)b 14.5 ± 1.42 7.8 ± 0.71 < 0.0001
EPO, ng/ml (mean ± SD)b 137.7 ± 81.5 638.4 ± 272.3 < 0.0001
Estrogen or testosterone, ng/ml (Mean ± SD)b 2.7 ± 0.9 0.63 ± 0.44 < 0.0001
OPG, pg/ml (mean ± SD)b 3931.2 ± 479.8 3370 ± 1142.4 0.004
RANKL, pg/ml (mean ± SD)b 2621.9 ± 578.9 4980.9 ± 1313.6 < 0.0001
RANKL/OPG ratio (mean ± SD)b 0.7 ± 0.22 1.66 ± 0.85 < 0.0001
P1NP, pg/ml (mean ± SD)b 269.4 ± 127.7 64.4 ± 52 < 0.0001
CTX, pg/ml (mean ± SD)b 185.9 ± 53.6 459.2 ± 120.1 < 0.0001
  1. Hb hemoglobin, EPO erythropoietin, OPG osteoprotegerin, RANKL receptor activator of NF-kappaB ligand, RANK receptor activator of NF-kappaB, P1NP N-terminal propeptide of type 1 collagen, CTX carboxy terminal collagen cross links
  2. aP-values were calculated by the Student’s t-test
  3. bData are presented as the mean ± standard deviation